Nav: Home

SGLT2 inhibitors can slow progression of chronic kidney disease

August 31, 2020

850 million people worldwide are affected by chronic kidney disease (CKD) - a worrying figure, and one that continues to rise. Treatment options for patients with CKD are multiple and often determined by the aetiology of CKD. So far, RAAS blockade (ACE inhibitors or angiotensin receptor blockers) was one of the most effective therapeutic intervention which has been shown to affect CKD disease progression. Now, SGLT2 inhibitors add significantly to the armentarium and provided another breakthrough in the management of CKD.

The first to realize this potential of SGLT2 inhibitors was Professor Christoph Wanner, co-author of the EMPA-REG OUTCOME trial and President of the ERA-EDTA. Wanner and his colleagues conducted the EMPA-REG OUTCOME trial [4], the aim of which was to investigate whether the SGLT2 inhibitor Empagliflozin could lower the rate of cardiovascular events in patients with T2D. "It could, but the much more exciting result for me as a nephrologist was an incidental finding of the study, which we analysed and published in a second paper [5]. It seemed that the medication could also slow progression of CKD. At that moment the effect was 'too good to be true' Wanner remembers, but this effect was confirmed in subsequent cardiovascular outcome trials (CVOTs) with other SGLT2 inhibitors [6, 7]. However, the proportion of patients with CKD in these CVOTs, which were conducted among patients with T2D, was relatively low.

At that point, the kidney study program with Canagliflozin was already underway. It was not until 2019 that the CREDENCE trial provided evidence that the SGLT2 inhibitor Canagliflozin could slow CKD progression in patients with T2D and CKD with albuminuria who were already on standard RAAS blockade and baseline glucose lowering therapy [3].

An important link was still missing, however. In about one third of all CKD patients, diabetes is the cause of kidney failure, but what about the other two thirds? Can SGLT2 inhibitors really help these patients, too, and prevent them from reaching end stage kidney disease in need of regular dialysis treatments or renal transplantation?

A new study (DAPA-CKD) was initiated to answer these questions and the results were presented at the virtual ESC Congress. Cardiologists welcomed the prominent treatment originating its effects in the kidney and extending to the heart. The rationale and protocol of the study had been published in Nephrology Dialysis Transplantation, the premier kidney journal in Europe [8], earlier this year. The results were groundbreaking: 4304 patients (67.5% had diabetes) were randomized 1:1 to dapagliflozin or placebo. The primary outcome of worsening of kidney function was a composite of sustained ?50% eGFR decline, occurrence of end stage kidney disease, or renal or CV death. There were 197 events in the dapagliflozin group and 312 in the placebo group; the HR for the primary endpoint was 0.61 (95% CI, 0.51-0.72; P=0.000000028) resulting in a number needed to treat of 19. The benefit of dapagliflozin on the primary endpoint was consistent in patients with and without T2D. No concerning safety signals were observed.

A study on the SGLT2 inhibitor Empagliflozin in 3730 heart failure patients (EMPEROR-Reduced) with and without T2D was already published the day before, saturday morning 8:30 am Eastern US-Time in "The New England Journal of Medicine" [2]. Although kidney parameters were analyzed as secondary endpoints, the results point in the same direction: The annual rate of decline in the estimated glomerular filtration rate was significantly slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml/min/1.73 m2 per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious kidney outcomes.

"All in all, this is great news for patients with CKD. For years, no new treatment option has proved to be safe and effective, which meant that no new drug could be introduced into clinical practice. We now have a whole new substance class that is obviously very effective. It is quite amazing how often important medical innovations derive from incidental discoveries. We wanted to find a therapy to improve cardiovascular outcomes in individuals with type 2 diabetes and found a long-awaited treatment to slow progression of chronic kidney disease, even in those who do not suffer from type 2 diabetes. It's a bit 'Flemingesque', at the beginning we did not realize the significance of our findings, now we have a kidney drug in hands" Wanner concludes.
-end-
[1] Farxiga met all primary and secondary endpoints in groundbreaking Phase III DAPA-CKD trial for the treatment of patients with chronic kidney disease. Press Release from AstraZeneca from 28 July 2020, https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease.html

[2] Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). NEJM 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2022190

[3] Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med 2019;380:2295-2306

[4] Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128

[5] Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-334

[6] Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657

[7] Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med 2019;380:347-357

[8] Heerspink HJL, Stefansson BV, Chertow GM et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020;35:274-282

About ERA-EDTA

With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide. It leads European nephrology and is one of the most important European medical associations. It organizes annual congresses and other educational and scientific activities. ERA-EDTA also produces guidelines, collects data, and performs epidemiological studies through its Registry. The association supports fellowships and educational/research projects through its committees and working groups. Its publications are NDT, CKJ (Open Access journal), and the online educational journal NDT-Educational.

Website http://www.era-edta.org

ERA-EDTA

Related Diabetes Articles:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.
Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.
Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).
Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.
Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.